These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31927919)

  • 21. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
    Svensson EM; Murray S; Karlsson MO; Dooley KE
    J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study.
    Tsuyuguchi K; Sasaki Y; Mitarai S; Kurosawa K; Saito Y; Koh T
    Respir Investig; 2019 Jul; 57(4):345-353. PubMed ID: 30745177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
    Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC
    Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333
    [No Abstract]   [Full Text] [Related]  

  • 25. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    Pandie M; Wiesner L; McIlleron H; Hughes J; Siwendu S; Conradie F; Variava E; Maartens G
    J Antimicrob Chemother; 2016 Apr; 71(4):1037-40. PubMed ID: 26747099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bedaquiline: a new drug approved for treatment of multidrug-resistant tuberculosis.
    Deoghare S
    Indian J Pharmacol; 2013; 45(5):536-7. PubMed ID: 24130398
    [No Abstract]   [Full Text] [Related]  

  • 28. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling.
    Mehta K; Balazki P; van der Graaf PH; Guo T; van Hasselt JGC
    Clin Pharmacokinet; 2024 May; 63(5):657-668. PubMed ID: 38530588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.
    Kurosawa K; Rossenu S; Biewenga J; Ouwerkerk-Mahadevan S; Willems W; Ernault E; Kambili C
    J Clin Pharmacol; 2021 Oct; 61(10):1344-1355. PubMed ID: 33991350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK; Dahiya N
    Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.
    Healan AM; Griffiss JM; Proskin HM; O'Riordan MA; Gray WA; Salata RA; Blumer JL
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB.
    Svensson EM; Karlsson MO
    J Antimicrob Chemother; 2017 Dec; 72(12):3398-3405. PubMed ID: 28961790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis.
    Cohen K; Maartens G
    Expert Opin Drug Saf; 2019 Oct; 18(10):875-882. PubMed ID: 31339384
    [No Abstract]   [Full Text] [Related]  

  • 35. Development and validation of an LC-MS/MS method for the simultaneous determination of bedaquiline and rifabutin in human plasma.
    Gray WA; Waldorf B; Rao MG; Stiles BL; Griffiss JM; Salata RA; Blumer JL
    J Pharm Biomed Anal; 2019 Nov; 176():112775. PubMed ID: 31446299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers.
    Healan AM; Salata RA; Griffiss JM; Proskin HM; O'Riordan MA; Gray WA; Blumer JL
    Clin Pharmacol Drug Dev; 2019 May; 8(4):436-442. PubMed ID: 30500116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A; Cobelens FG; Cohen T
    PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
    Park S; Lee KM; Kim I; Mok J
    Int J Infect Dis; 2018 Nov; 76():88-90. PubMed ID: 30244076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.